Use of glucocorticoids in the management of immunotherapy‐related adverse effects

Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy‐related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hanping, Zhou, Jiaxin, Guo, Xiaoxiao, Li, Yue, Duan, Lian, SI, Xiaoyan, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529549/
https://www.ncbi.nlm.nih.gov/pubmed/32893490
http://dx.doi.org/10.1111/1759-7714.13589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529549/
https://www.ncbi.nlm.nih.gov/pubmed/32893490
http://dx.doi.org/10.1111/1759-7714.13589

Ejemplares similares